Your Cart Is Empty!
Horizon to provide human genomic reference standards to assure quality and performance of Transgenomic’s Multiplexed ICE COLD-PCR kits
CAMBRIDGE, UK, and OMAHA, NE, USA (April, 23, 2015)Horizon Discovery Group plc (LSE:HZD) (Horizon), the international life science company supplying research tools and services that power genomics research and the development of personalized medicines, and Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology and inherited diseases through advanced diagnostic tests and clinical and research services, today announced a new Original Equipment Manufacture (OEM) agreement to incorporate Horizon’s human genomic reference standards, produced by Horizon’s Diagnostics division, into Transgenomic’s Multiplexed ICE COLD-PCRTM (MX-ICP) kits for use in research and clinical applications. Further details of the agreement were not disclosed.
Why should laboratories be using Genomic DNA rather than Plasmids and what are the advantages?
In molecular biology, plasmid DNA has proved to be a vital tool for many applications. However, when developing or validating assays which will ultimately measure human genomic DNA samples, plasmid DNA may not be an ideal control sample.
Hosted by CAP Today April-28-2015
Veterans of the industry (Chris Corless, MD PhD & Josh Deigan, PhD) will be presenting 4 key topics on molecular quality control. This webinar will empower you to better understand quality control in the workplace.
Formalin-Fixed, Paraffin Embedded Sections on Slide - Routinely monitor your Assay
The availability of genetically defined reference materials offers an industry standard for development and quality control of IHC assays, directly improving the accuracy and reproducibility. IHC HDx™ Reference Standards provide laboratories with a consistent source of positive and negative reference material on one slide.
At Horizon Diagnostics, we are constantly looking to develop easier and simpler ways of doing business.
To save you time, we've upgraded our website and ordering system to make it much more convenient to place orders. In doing so, and to comply with data protection acts, you will be required to register for a new account to order online. As a pre-existing account holder we encourage you to sign up for a new account at www.horizondx.com.
18/04/2015 | Philadelphia, PA, USA
The AACR Annual Meeting 2015 will highlight the latest, most exciting discoveries in every area of cancer research and will provide a unique opportunity for investigators from all over the world to meet, interact, and share their insights.
Horizon’s Reference Materials chosen by ArcherDX to validate its FusionPlex test for non-small cell lung cancer markers
Cambridge, UK, and Boulder, CO, USA, 23rd March 2015: Horizon Discovery Group plc (LSE:HZD) (Horizon), the international life science company supplying research tools and services that power genomics research and the development of personalized medicines, and ArcherDX, Inc., a leader in Next Generation Sequencing (NGS) fusion detection, today announced they have signed an Original Equipment Manufacture (OEM) agreement that will see Horizon’s Reference Materials supplied as a standalone product alongside ArcherDX’s Archer™FusionPlex™ to aid customer validation of its ALK fusion assay kits.
In a first, an Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor IRESSA® (gefitinib) has received European label indication recommending the use of cell-free DNA from a blood sample when obtaining a tumour sample from a patient is not possible. This label change is based on the results of a collaboration between AstraZeneca and Qiagen.
IRESSA acts by blocking the transmission of signals involved in the growth and spread of tumors and is approved in 90 countries for the treatment of adult patients with locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC).
1-10 of 15
Send us a message
See our ordering page
Click here to register with us
More about shipping